Core Insights - SBC Medical Group Holdings is transitioning from a domestic platform to a globally scalable model, with a focus on the U.S. market and long-term growth strategies [3][4] Financial Performance - Average revenue per visit increased by 11% year-over-year to $316 in Q4, indicating a recovery from previous revenue compression [4] - The company reported a disciplined transition year in 2025, with revenue decline due to structural changes, while net income grew by 9% and margins remained stable [4] Market Positioning - SBC Medical aims to differentiate itself in the fragmented U.S. aesthetic market through a system-driven approach that enhances clinical quality, customer retention, and operational efficiency [3][4] - The company has established a minority investment in OrangeTwist, marking its entry into the U.S. market [4] Business Model - SBC Medical operates a capital-light business model, achieving EBITDA margins above 40% across 283 locations with 6.63 million annual patient visits [4] - The company is focused on long-term growth initiatives, including AI-driven operational infrastructure and expansion into Japan's $34 billion longevity market [4] Strategic Initiatives - The company is actively expanding its global presence, particularly in the U.S. and Asia, through direct operations and medical tourism initiatives [5] - SBC Medical was listed on Nasdaq in September 2024 and included in the Russell 3000® Index in June 2025, enhancing its visibility in the market [5]

Investor Presentation 4Q and Full Year 2025 March 2026 Disclaimer This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company' ...

Core Insights - Jupiter Neurosciences, Inc. is launching its Nugevia e-commerce platform and three nutraceutical supplements, marking a significant expansion into the longevity market valued at $8 trillion [2][3][4] - The Nugevia product line utilizes the patented JOTROL resveratrol delivery platform, which has shown a nine-fold increase in bioavailability, aiming to bring pharmaceutical-grade science to the consumer health sector [3][11] - The launch is seen as a pivotal moment for the company, establishing a new revenue stream that supports ongoing research and development while enhancing financial flexibility [4][5] Company Strategy - Jupiter Neurosciences is executing a dual-path business model that focuses on both CNS therapeutic programs and the consumer longevity market [3][8] - The introduction of Nugevia is intended to create a capital-efficient growth engine, allowing the company to leverage its clinical research for consumer products [4][5] - The company aims to build a diversified and sustainable business that complements its pharmaceutical pipeline [4] Product Details - The Nugevia product line includes Nugevia GLO for skin vitality, Nugevia PWR for mitochondrial health, and Nugevia MND for cognitive support, all utilizing the JOTROL technology [9][12] - Pre-orders for the products are available on the Nugevia website, with shipping expected to start in Fall 2025 [7] Brand Ambassadors - Annika Sörenstam and Chris Webber have been appointed as the first brand ambassadors for Nugevia, enhancing the brand's visibility and credibility [6]

Core Viewpoint - Jupiter Neurosciences, Inc. has launched a new consumer longevity supplement line called Nugevia, with Annika Sörenstam as the brand ambassador, emphasizing science-backed formulations for performance and healthy aging [1][2][3] Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on neuroinflammation and healthy aging, advancing a therapeutic pipeline for CNS disorders while entering the consumer longevity market with Nugevia [6][10] - The company utilizes JOTROL, a patented resveratrol-based micellar delivery platform, which enhances bioavailability and supports both clinical-stage therapies and the Nugevia supplement line [4][9][10] Product Details - Nugevia's initial formulations include GLO, MND, and PWR, designed to support skin vitality, cognitive resilience, and mitochondrial function, respectively [4][10] - The longevity market is projected to reach $8 trillion by 2030, indicating significant growth potential for Nugevia and its revenue-generating capabilities to support ongoing clinical development [4] Brand Ambassador - Annika Sörenstam, a Hall of Fame golfer with over 95 international tournament victories, will advocate for Nugevia, aligning her values of longevity and performance with the brand's mission [2][11] - Sörenstam's collaboration emphasizes the importance of scientific backing in health products, reflecting her commitment to a healthy lifestyle [3][4]